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Abstract Background and Objectives: Stenosing tenosynovitis (trigger finger) is one of
the most common causes of pain and disability in the hand, which may often
require treatment with anti-inflammatory drugs, corticosteroid injection, or
open surgery. However, there is still large room for improvement in the
treatment of this condition by corticosteroid injection. Themechanical, visco-
elastic, and antinociceptive properties of hyaluronic acid may potentially
support the use of this molecule in association with corticosteroids for the
treatment of trigger finger. This study examines the feasibility and safety of
ultrasound-guided injection of a corticosteroid and hyaluronic acid com-
pared, for the first time, with open surgery for the treatment of trigger finger.
Methods: This was a monocentric, open-label, randomized study. Consec-
utive patients aged between 35 and 70 years with ultrasound-confirmed
diagnosis of trigger finger were included. Patients were randomly assigned to
either ultrasound-guided injection of methylprednisolone acetate 40mg/mL
with 0.8mL lidocaine into the flexor sheath plus injection of 1mL hyaluronic
acid 0.8% 10 days later (n= 15; group A), or to open surgical release of the
first annular pulley (n = 15; group B). Clinical assessment of the digital ar-
ticular chain was conducted prior to treatment and after 6 weeks, and 3, 6,
and 12 months. The duration of abstention from work and/or sports activity,
and any treatment complications or additional treatment requirements (e.g.
physiotherapy, compression, medication) were also recorded.
Results: Fourteen patients (93.3%) in group A had complete symptom reso-
lution at 6 months, which persisted for 12 months in 11 patients (73.3%), while
three patients experienced recurrences and one experienced no symptom im-
provements. No patients in group A reported major or minor complications
during or after corticosteroid injection, or required a compression bandage. All
15 patients in group B achieved complete resolution of articular impairment by
3 weeks after surgery, but ten patients were assigned to physiotherapy and local
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and/or oral analgesics for complete resolution of symptoms, which was approxi-
mately 30–40 days postsurgery. The mean duration of abstention from work
and/or sport was 2–3 days in group A and 26 days in group B.
Conclusions: Although the limited sample size did not allow any statistical
comparison between treatment groups, and therefore all the findings should
be regarded as preliminary, the results of this explorative study suggest that
ultrasound-guided injection of a corticosteroid and hyaluronic acid could be
a safe and feasible approach for the treatment of trigger finger. It is also
associated with a shorter recovery time than open surgery, which leads to a
reduced abstention from sports and, in particular, work activities, and there-
fore may have some pharmacoeconomic implications, which may be further
explored. In light of the promising results obtained in this investigation,
further studies comparing ultrasound-guided injection of corticosteroid plus
hyaluronic acid with corticosteroid alone are recommended in order to clarify
the actual benefits attributable to hyaluronic acid.
Introduction
Stenosing tenosynovitis, otherwise known as
trigger finger (TF), affects the flexor pollicis lon-
gus or flexor digitorum tendons, and causes a
characteristic painful tendon snap or click on
flexion and extension, and/or locking of the meta-
carpophalangeal or proximal interphalangeal
joints of the involved digit. Most cases are idio-
pathic. Entrapment of the affected tendon at the
first annular (A1) pulley occurs because of a dif-
ference in the diameter of the flexor tendon and
its sheath as a result of thickening of the sheath
and some localized tendon thickening. Chronic
repetitive friction between the tendon and its
sheath may then lead to an intratendinous nodule
at the A1 pulley.[1]
TF is one of the most common causes of pain
and disability in the hand with an incidence of
around 28 cases per 100 000 population per year,
or a lifetime risk of 2.6% in the general popu-
lation.[1] In adults, it occurs more commonly in
women than in men, usually in the dominant hand,
and most often in the thumb or ring fingers.[1]
The aim of treatment is abolition of pain and re-
storation of a full range of smooth motion in the
involved digit(s).[2] Current treatment options in-
clude either conservative management by splint-
ing,[1] treatment with anti-inflammatory drugs or
corticosteroid injection (usually with local anes-
thetic) in the flexor tendon sheath,[2-10] or surgical
release of the A1 pulley (via an open or percuta-
neous approach).[11-14]
Although there are no well controlled studies
comparing treatment modalities, corticosteroid
injection is widely accepted as first-line treatment
of TF; surgery is generally reserved for cases of
corticosteroid treatment failure or for patients
with more severe articular locking and joint rigid-
ity.[2,4,9,13] Certainly surgery is the definitive
treatment, providing permanent resolution of symp-
toms,[4,13] but corticosteroid injection is often
preferred, not only because a single injection is
effective in a large proportion of patients, but
also because it can be given in an office setting
and is a relatively simple, low-cost procedure.[4]
However, symptoms may not resolve with only
one corticosteroid injection and the likelihood of
success decreases with each subsequent injection
(60% of 109 trigger digits after the first injection,
36% after the second, and 33% after the third;
for those patients requiring more than one injec-
tion, average duration of relief from injection was
14 weeks, and ranged from 4 to 40 weeks).[4] There
is some room for improvement in the treatment
of TF by corticosteroid injection.
The glycosaminoglycan hyaluronic acid
(HA) is an essential component of the connective
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tissue[15] and is naturally found in the synovial
fluid. HA injection has been used in the effective
and safe treatment of osteoarthritis of the hip,
knee, and other joints with success rates varying
from 68% to 95%.[16-21]
Several properties of HA support its use in
combination with corticosteroid injection in pa-
tients with TF. We hypothesize that HA may act
initially as a mechanical intermediary via its visco-
supplementing properties (by immediate recovery
of synovial fluid viscosity),[15,18,19,22,23] conse-
quently enlarging the tendon passageway narrowed
by the disease and thereby regaining enough space
for the tendon to glide normally. Subsequently, for
3–7 days after injection, HA not only provides
shock absorption via its rheologic (visco-elastic)
properties, but it has an antinociceptive effect and
also significantly decreases the expression of pro-
inflammatory cytokines in the synovial space.[19]
In addition, experimental studies show that HA
has a direct effect on tendons by inhibiting and
modulating fibroblast activity impaired by sten-
osing tenosynovitis.[19,23,24] To the best of our
knowledge, there are no studies to date on the use
of HA in the treatment of TF.
The aim of this explorative study was to es-
tablish the feasibility and safety of injection of
a corticosteroid followed by HA in the treatment
of TF, using surgery as the reference treatment,
because in the study institution, surgery is the
treatment of choice for TF, and a conservative
infiltration treatment with corticosteroid is only
seldom prescribed. The relatively new method for
corticosteroid injection of ultrasound-guided in-
jection was employed because of its very high
long-term success rate (90% of digits at 1 year
post injection),[25] and potential to be more ac-
curate and safer than blind injection.[7] This pro-
cedure allows data to be obtained that is as free as
possible from the potential errors associated with
infiltrative procedures.
Methods
Subjects and Study Design
This was a prospective, open-label, randomized,
single-center study. Consecutive patients aged
between 35 and 70 years presenting with clinical
signs and symptoms of stenosing tenosynovitis of
the flexor tendons and in whom diagnosis was
confirmed by ultrasound (in order to exclude
other conditions that may be associated with the
same symptoms, e.g. luxations, joint abnormal-
ities, focal dystony) were eligible for enrollment.
Ultrasound diagnosis was based on the criteria
described previously by Ebrahim et al.,[26] which,
briefly, were as follows: hypoechoic thickening of
the A1 pulley; visualization of a nodule in the
flexor superficialis tendon; bow-stringing of the
pulley during flexion; and visualization of trigger-
ing (obstruction of the tendon passing through
the osteofibrous canal in the pulley during flex-
ion-extension) of the involved digit. Patients with
grade IV TF or the following co-morbidities were
excluded: diabetes mellitus; rheumatoid arthritis;
hypercholesterolemia; hypotension; and hyper-
tension. This choice was taken in order to avoid
changes associated with alterations in the syno-
vial and intratendinous microcirculation.
Disease severity was graded according to
Froimson’s modification[27] of Quinnell’s classi-
fication,[28] as follows: grade I (pre-triggering) –
pain and a history of catching, not demonstrable
on clinical examination; grade II (active trigger-
ing) – demonstrable actively correctable catching;
grade III (passive triggering) – demonstrable
passively correctable catching (III A) or impossible
active flexion (III B); and grade IV (contracture)
– uncorrectable fixed flexion. This observational
study was performed in accordance with the
Declaration of Helsinki as part of routine clinical
practice based on two treatment options; full
ethical approval was therefore not required. The
nature of the study was fully explained to par-
ticipating patients who consented to use of their
data for purposes of clinical study.
Interventions
Patients were randomly assigned to cortico-
steroid injection plus HA injection (group A) or
open surgery (group B). In group A, the cortico-
steroid injection was administered according to
methods detailed in Bodor and Flossman,[25] in a
sterile environment under ultrasound guidance.
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Briefly, a Philips IU22 ultrasound system with
high-frequency linear-array probe 17MHz (figure 1)
was positioned on the volar aspect of the hand
and a 25-gauge needle was used to inject methyl-
prednisolone acetate 40mg/1mL (Depo-medrol,
Pfizer, Italy) with 0.8mL lidocaine chlorhydrate
2% (S.A.L.F., Bergamo, Italy) into the sheath
of the flexor tendons, distally to the A1 pulley
(figure 2). Ten days later, 1mL 0.8%HA (Sinovial
Mini, Yaral Mini, IBSA Institut Biochimique
SA, Pambio-Noranco, Switzerland) was injected
using the same technique (figure 3). The time period
of 10 days was chosen because, in our experience,
10 days are required to observe the maximum effect
of corticosteroid therapy.
Group B patients underwent open surgery by
conventional technique under locoregional anes-
thesia and a haemostatic pressure cuff inflated
around the upper arm. The procedure was carried
out on a day surgery basis and patients were dis-
charged in the evening with a compression dress-
ing to be kept in place for 4 days until it was
changed in the outpatient clinic. Sutures were re-
moved 2 weeks after surgery. At the first follow-up
visit, patients were advised to mobilize the finger,
depending on the level of pain experienced.
Endpoints and Assessments
Clinical assessment of the digital articular
chain was conducted prior to treatment and after
6 weeks, and 3, 6, and 12 months. The duration
of abstention from work and/or sports activity,







Fig. 1. Puncture: longitudinal scan of the flexor tendons of the fourth finger using a high frequency (17Mhz) linear probe over the meta-
carpophalangeal joint. The 25G needle is clearly displayed (empty white arrow) with its tip at the tendon sheath distal to the A1 pulley (full white
arrow). The X and bar on the right are markers of focus in the US display (X is the center, and the bar is the range of focus). FPT = flexor






Fig. 2. Corticosteroid injection: longitudinal scan of the flexor tendons of the fourth finger using a high frequency (17Mhz) linear probe over
the metacarpophalangeal joint. The 25G needle is clearly displayed (empty white arrow) with its tip at the tendon sheath distal to the A1 pulley
(full white arrow). The drug is injected into the proximal recess of the tendon sheath (empty arrowhead). The X and bar on the right are markers
of focus in the US display (X is the center, and the bar is the range of focus). FPT = flexor profundus tendon; FST = flexor superficialis tendon;
MCH =metacarpal head; PP =proximal phalange.
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treatment requirements (e.g. physiotherapy, com-
pression, medication) were also recorded for each
patient. The primary endpoint was the proportion
of patients with a ‘satisfactory’ outcome; clinical
outcome was deemed satisfactory if there was a
resolution of symptoms in the first 6 weeks with no
recurrence in the first 3 months, and if resolution
persisted until the 6-month assessment. The change
in symptom severity, graded according to the
Quinnell-Green classification,[27,28] was also asses-
sed in each patient before and after treatment.
All patients were assessed before and after treat-
ment using the Disabilities of the Arm, Shoulder
and Hand (DASH) questionnaire,[29] the Satisfac-
tion Visual Analog Scale (SVAS),[29] and a pain
Visual Analog Scale (VAS).[30] The DASH is a
30-item questionnaire that records patient-reported
outcomes on a Likert scale from 1 to 5, giving a
total score (ranging from 30 to 150), which is then
converted to a percentage, where 0% indicates no
disability and 100% is the most severe disability.[29]
Due to the explorative nature of this study, we did
not perform any calculation of statistical power or
any kind of statistical comparison between groups.
Results
Demographics
A total of 10 men and 20 women, with an
average age of 52.5 years, were enrolled between
1 January and 31 May 2007, and treated. Disease
severity was grade II in 14 patients and grade III
in 16 patients. All were single, idiopathic cases:
the thumb was involved in 16 patients, the ring
finger in seven, and the long finger in seven. No
patient had more than one finger affected or had
co-existing syndromes such as carpal tunnel or
Dupuytren’s disease. Pain and associated dys-
function had been present for an average period
of 3.5 months (range 1–6 months) prior to treat-
ment; 40% of patients had difficulty undertaking
daily life activities due to impaired grip strength,
while the remaining 60% reported milder symp-
toms only partly interfering with their normal
occupations and sports activity. Patients were
equally distributed for age, sex, occupation, and
severity and duration of symptoms between the
two treatment groups.
Outcomes
At 6 months’ follow-up, complete symptom
resolution was observed in 14 of 15 (93.3%)
patients in group A, with a residual deficit of 7 in
only one patient. At 12 months after treatment,
11 of 15 (73.3%) patients still had complete res-
olution of symptoms, three (20.0%) had experi-
enced a recurrence, but the severity had passed
from grade III to grade I, and one patient (6.7%)
had no symptom improvement. All 15 patients in
group B achieved complete resolution of articular
impairment by 3 weeks after surgery, but ten pa-







Fig. 3. Hyaluronic acid injection: longitudinal scan over the flexor tendons of the fourth finger using a high frequency (17Mhz) linear probe
over the metacarpophalangeal joint. The 25G needle is clearly displayed (empty white arrow) with its tip at the tendon sheath distal to the A1
pulley (full white arrow). Two weeks after corticosteroid injection, low-medium molecular weight hyaluronic acid is injected using the same
technique into the synovial space (empty arrowheads) releasing the walls of the tendon sheath. The X and bar on the right are markers of
focus in the US display (X is the center, and the bar is the range of focus). FPT = flexor profundus tendon; FST = flexor superficialis tendon;
MCH =metacarpal head; PP =proximal phalange.
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analgesics for complete resolution of symptoms,
which was approximately 30–40 days postsurgery.
Excluding very mild local pain for 12–36 hours,
which was reported in three patients, no patients
in group A reported major or minor complica-
tions during or after corticosteroid injection, or
required a compression bandage. In group B,
seven patients experienced scar pain, two patients
had an abnormal flexion of the finger, and one
patient presented a mild algodystrophic syndrome,
which resolved after therapy. Recovery time was
also faster with ultrasound-guided injection of a
corticosteroid and HA than with surgery; the
mean duration of abstention from work and/or
sport was 2–3 days in group A and 26 days (range
20–30 days) in group B as shown in table I.
Patient-reported outcomes for pain, disability,
and patient satisfaction assessed according to the
VAS, DASH, and SVAS scores were satisfactory
in group A patients and similar to those in group
B patients (table II).
Discussion
Our findings show that ultrasound-guided in-
jection of a corticosteroid and HA yielded satis-
factory outcomes in 14 of 15 (93.3%) patients
6 months after treatment. The outcomes remained
unchanged at 12 months’ clinical follow-up in
11 of 15 (73.3%) patients. This infiltrative therapy
regimen also led to faster recovery with fewer
complications and required less additional treat-
ment than open surgery; however, this finding is
somehow conflicting with other evidence, which
has suggested that the higher costs associated with
surgery may be ultimately offset by the benefit
conferred through permanency of relief.[4] The
faster recovery times associated with this infiltrative
regimen, when compared with those following
open surgery, led to an approximate 10-fold de-
crease in abstention from sporting and, in particular,
work activities. This may have some pharmaco-
economic implications, which may be further ex-
plored. Patient-reported outcomes for disability,
satisfaction, and pain were satisfactory in patients
treated with ultrasound-guided corticosteroid
and HA injection, and similar to those obtained
in patients who received surgical treatment.
Open surgery is considered the gold standard
for the treatment of TF,[4,13] and we therefore
chose it as a control to assess the feasibility of
ultrasound-guided injection of a corticosteroid
and HA. As expected, in this study, open surgery
was associated with a complete resolution of arti-
cular symptoms, while the conservative approach
resulted, in a limited number of cases, in recur-
rences, possibly due to the fact that the anatomical
Table I. Duration of abstention from physical work/sport (P), office
work (O), or normal household work (N) as a result of the treatment in




Kind of work Abstention from
work/sport (days)
Group A
Female 35 P 3
Female 62 O 2
Male 47 P 3
Female 42 P 3
Male 69 P 3
Female 59 N 2
Female 55 O 2
Male 51 P 3
Male 46 P 3
Female 61 N 2
Male 56 O 2
Female 52 N 2
Female 61 O 2
Female 46 P 3
Male 51 O 2
Group B
Male 53 O 20
Female 51 O 29
Female 40 P 33
Female 50 N 21
Male 42 P 40
Female 70 N 23
Male 48 P 31
Female 41 O 28
Male 55 O 21
Female 50 N 26
Female 51 N 24
Female 55 O 22
Female 48 P 31
Female 59 O 21
Female 69 N 20
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structures remain unmodified. However, the ul-
trasound-guided injection of a corticosteroid and
HA provided an overall favorable clinical out-
come and some potential advantages (e.g. a short
recovery time and few complications after the
procedure), which deserve further investigation.
Corticosteroid injection into the sheath of the
flexor tendons as a conservative treatment based
on the anti-inflammatory effect of corticosteroids
dates back to the 1950s. Since then, local corti-
costeroid injections have been assessed in many
reports, with different outcomes, and long-term
efficacy rates between 60% and 93% obtained
with between one and four injections.[2,4-6,8] As
emphasized in the review by Kelly et al.,[31] no
literature reports are currently available on the
use of HA to treat stenosing tenosynovitis of the
flexor tendons, but the results of our study ap-
pear to compare favorably with those obtained
in other studies utilizing injection of methyl-
prednisolone acetate. A retrospective review of
76 digits in 50 patients treated with methyl-
prednisolone acetate or triamcinolone diacetate
showed complete resolution of symptoms in
82% of digits for a mean follow-up period of
35months.[5] Of these, a single injection was needed
for 42 digits, two injections for 11 digits, three
injections for six digits, and four injections for
three digits. A second study prospectively followed
77 digits in 58 patients for an average of 4.6 years
following injection of methylprednisolone ace-
tate.[10] A total of 61% of digits showed complete
resolution of symptoms after a single injection,
27% reported recurrent episodes, and 12% failed
or required surgery because of early recurrence.
Finally, a double-blind, randomized study showed
a success rate of 60% in patients treated with in-
jection of methylprednisolone acetate plus anes-
thetic compared with 16% in those treated with
anesthetic alone (p = 0.02).[8] However, in all of
these studies, corticosteroid injection was not ul-
trasound-guided and no information regarding
the severity of disease or duration of symptoms
was reported, so direct comparison with our study
cannot be made.
Such a wide variation in efficacy rates can be
explained by many factors. Obviously, injection
of the drug into the correct location will enhance
the likelihood of a successful outcome and preclude
many of the complications associated with the
procedure. For this reason, ultrasound guidance
is deemed the most accurate technique to ensure
an optimal result, especially in an anatomically
difficult location such as the hand, requiring in-
jection into a virtual space such as the flexor
tendon sheath, and avoiding iatrogenic injury.[7]
Table II. Mean scores (range) for disability (Disabilities of the Arm, Shoulder and Hand [DASH] questionnaire), patient satisfaction (Sat-
isfaction Visual Analog Scale [SVAS]) and pain (visual analog scale [VAS]) in patients treated for trigger finger with ultrasound-guided injection
of a corticosteroid and hyaluronic acid (group A) or open surgery (group B)
Questionnaire Timepoint Group A (n =15) Group B (n =15)
Disability (DASH)a Pre-treatment 31% (16–48%) 33% (18–47%)
6mo 13% (7–20%) 11% (7–16%)
Patient satisfaction (SVAS)b 3mo 8.2 (3–10) 8.4 (4–10)
6mo 7.4 (2–10) 7.8 (3–10)
Pain (VAS)c Pre-treatment 4 (6–3) 4 (7–3)
6mo 1 (3–0) 1 (2–0)
a The DASH is a 30-item questionnaire that records patient-reported outcomes on a Likert scale from 1 to 5, giving a total score (ranging from
30 to 150), which is then converted to a percentage, where 0% indicates no disability and 100% is the most severe disability.
b The SVAS consists of a 100mm-long horizontal line ranging from ‘completely satisfied’ to ‘totally unsatisfied’. On top of the scale the
question: ‘‘Are you satisfied with your treatment of trigger finger?’’ was placed. The patients represent their perception of the amount of
satisfaction they feel by marking a horizontal line. The VSAS score is measured in mm from the left hand end of the line to the point
indicated by the patient. The values in our table are reported in cm.
c The VAS of pain is an instrument used to measure the amount of pain a patient feels. The VAS of pain is usually a 100mm-long horizontal
line, which may contain word descriptors at each end (no pain in the left end, severe pain in the right end). The patients represent their
perception of the amount of pain they feel by marking a horizontal line. The VAS score is measured in mm from the left hand end of the line
to the point indicated by the patient. The values in our table are reported in cm.
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Corticosteroid administration carries the risk of
complications such as adipose necrosis, skin depig-
mentation, dermal or epidermal atrophy, infec-
tion, and tendon rupture.[1] These adverse effects
have occurred following corticosteroid injec-
tion without ultrasound guidance; therefore,
certain complications are presumably due to in-
correct deployment of the drug,[3,8] as well as di-
rect tendon puncture and the undesired effects of
corticosteroids.
The use of ultrasound-guided injection of
corticosteroids and HA may be associated with a
relevant cost (in Italy, about h180 if the proce-
dure is performed outside the National Health-
care System, on a private basis [2010 values]).
However, these costs are likely to be lower than
those determined by the gold standard for the
treatment of TF (i.e. open surgery). Moreover,
ultrasound-guided injection of corticosteroids
and HA appears, in this preliminary study, to be
associated with a high proportion of patients
achieving disease resolution and with a short re-
covery time (in turn reducing abstention from
working and sporting activities), without significant
post-procedural complications. These potential
advantages should be taken into consideration
for a full evaluation of the cost/benefit ratio of
ultrasound-guided injection of corticosteroids
and HA.
It is important to point out that this study has
a number of limitations that must be acknowl-
edged and discussed to better clarify the potential
implications on future research. A lack of a cortico-
steroid-only treatment arm means that any bene-
fits of adding HA to the regimen of injection
compared with corticosteroid alone cannot be
shown. In light of the promising results obtained
in this investigation, further study comparing ul-
trasound-guided injection of corticosteroid plus
HA with corticosteroid alone, or exploring other
treatment strategies (e.g. no ultrasound-guided
injection, corticosteroid only vs surgery) is re-
commended. Also, due to small patient numbers
in this study, it is not possible to analyze for any
trends in the duration of symptoms or number of
injections and success rates. Further studies with
a larger sample size are likely to provide new
insights on the effectiveness and safety of ultra-
sound-guided injection of corticosteroid plus HA.
It also must be acknowledged that, due to the
explorative nature of this study and the low
number of patients enrolled, neither a calculation
of power nor a statistical comparison between
groups were performed.
Conclusion
Ultrasound-guided injection of corticosteroids
and HA appears a safe and feasible option in the
treatment of TF. While open surgery remains the
reference treatment in terms of symptom reso-
lution, the reduced need for physiotherapy and
additional medications, suggesting lower costs,
and in particular the short recovery time asso-
ciated with ultrasound-guided injection of corti-
costeroids and HA may support a further evalu-
ation of the use of this infiltrative therapy for the
treatment of TF.
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